These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 12768299

  • 1. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K, Yamamoto T, Sawada K, Ohmichi M, Tasaka K, Murata Y.
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y, Liu J, Xing S, Xu R, Zhang Z, Wang Y.
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [Abstract] [Full Text] [Related]

  • 4. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ.
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [Abstract] [Full Text] [Related]

  • 5. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA, Going SB, Houtkooper LB, Flint-Wagner HG, Figueroa A, Metcalfe LL, Blew RM, Sharp SC, Lohman TG.
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [Abstract] [Full Text] [Related]

  • 6. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Apr; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 7. Treatment for patients with postmenopausal osteoporosis who have been placed on HRT and show a decrease in bone mineral density: effects of concomitant administration of vitamin K(2).
    Hidaka T, Hasegawa T, Fujimura M, Sakai M, Saito S.
    J Bone Miner Metab; 2002 Apr; 20(4):235-9. PubMed ID: 12115070
    [Abstract] [Full Text] [Related]

  • 8. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
    Ortiz Núñez DA, Mengchún López G, Hernández Marín I, Mendoza R, Ayala Ruíz AR.
    Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Some problems of postmenopausal osteoporosis prevention with hormone replacement therapy].
    Liu JL.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Jun; 25(3):240-3. PubMed ID: 12905731
    [Abstract] [Full Text] [Related]

  • 11. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women.
    Armamento-Villareal RC, Napoli N, Klug T, Civitelli R.
    Bone; 2004 Sep; 35(3):682-8. PubMed ID: 15336604
    [Abstract] [Full Text] [Related]

  • 12. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.
    Lukert BP, Johnson BE, Robinson RG.
    J Bone Miner Res; 1992 Sep; 7(9):1063-9. PubMed ID: 1329440
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [Abstract] [Full Text] [Related]

  • 15. Hormone replacement therapy in postmenopausal women.
    Yasui T, Uemura H, Takikawa M, Irahara M.
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [Abstract] [Full Text] [Related]

  • 16. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR.
    Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490
    [Abstract] [Full Text] [Related]

  • 17. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M, Vacca F.
    Minerva Med; 2004 Dec 20; 95(6):507-20. PubMed ID: 15785435
    [Abstract] [Full Text] [Related]

  • 18. [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
    MMW Fortschr Med; 2004 Aug 05; 146(31-32):53. PubMed ID: 15529718
    [No Abstract] [Full Text] [Related]

  • 19. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S, Dragomir A, Desgagné A, Blais L, Rossignol M, Blouin J, Moride Y, Ste-Marie LG, Fernandès JC.
    Pharmacoepidemiol Drug Saf; 2005 Oct 05; 14(10):685-95. PubMed ID: 15645517
    [Abstract] [Full Text] [Related]

  • 20. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 05; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.